434 related articles for article (PubMed ID: 26597115)
21. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
22. Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.
Gao H; Deng L
Cell Biochem Biophys; 2014 Mar; 68(2):419-25. PubMed ID: 23975598
[TBL] [Abstract][Full Text] [Related]
23. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
24. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Tei H; Miyake H; Fujisawa M
Hum Cell; 2015 Jul; 28(3):114-21. PubMed ID: 25862630
[TBL] [Abstract][Full Text] [Related]
25. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
26. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
[TBL] [Abstract][Full Text] [Related]
27. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
28. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
[TBL] [Abstract][Full Text] [Related]
29. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
30. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
31. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
32. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
33. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
[TBL] [Abstract][Full Text] [Related]
35. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
Zhu Y; Liu H; Xu L; An H; Liu W; Liu Y; Lin Z; Xu J
Cell Death Dis; 2015 Feb; 6(2):e1637. PubMed ID: 25675297
[TBL] [Abstract][Full Text] [Related]
36. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
[TBL] [Abstract][Full Text] [Related]
37. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
Sato M; Nakai Y; Nakata W; Yoshida T; Hatano K; Kawashima A; Fujita K; Uemura M; Takayama H; Nonomura N
PLoS One; 2013; 8(9):e74313. PubMed ID: 24073208
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
39. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-497 suppresses renal cell carcinoma by targeting VEGFR-2 in ACHN cells.
Pengcheng S; Ziqi W; Luyao Y; Xiangwei Z; Liang L; Yuwei L; Lechen L; Wanhai X
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28465356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
